Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M234,329Revenue $M58,831Net Margin (%)17.6Z-Score3.4
Enterprise Value $M243,595EPS $3.7Operating Margin %19.1F-Score7
P/E(ttm))21.7Cash Flow Per Share $0Pre-tax Margin (%)20.3Higher ROA y-yY
Price/Book3.110-y EBITDA Growth Rate %-0.7Quick Ratio1.1Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %-4.6Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %7.2ROA % (ttm)8.5Higher Current Ratio y-yY
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)15.0Less Shares Outstanding y-yY
Payout Ratio %66.0Shares Outstanding M2,419ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSLee Ainslie 2014-09-30 Buy 0.38%$85.25 - $94.8
($90.27)
$ 96.877%New holding, 272570 sh.272,570
NVSRuane Cunniff 2014-09-30 Buy $85.25 - $94.8
($90.27)
$ 96.877%New holding, 7772 sh.7,772
NVSHOTCHKIS & WILEY 2014-09-30 Reduce-0.21%$85.25 - $94.8
($90.27)
$ 96.877%Reduce -98.51%9,646
NVSPRIMECAP Management 2014-09-30 Reduce-0.16%$85.25 - $94.8
($90.27)
$ 96.877%Reduce -6.74%22,239,448
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 96.8710%Add 10.04%51,102,219
NVSHOTCHKIS & WILEY 2014-06-30 Reduce-0.52%$82.51 - $90.98
($87.73)
$ 96.8710%Reduce -71.8%649,519
NVSLee Ainslie 2014-06-30 Sold Out -0.42%$82.51 - $90.98
($87.73)
$ 96.8710%Sold Out0
NVSLee Ainslie 2014-03-31 Add0.1%$78.2 - $83.82
($81.23)
$ 96.8719%Add 31.52%351,580
NVSPRIMECAP Management 2014-03-31 Reduce-0.26%$78.2 - $83.82
($81.23)
$ 96.8719%Reduce -10.13%24,014,586
NVSLee Ainslie 2013-12-31 Reduce-0.56%$72.96 - $80.39
($77.55)
$ 96.8725%Reduce -66.76%267,321
NVSChris Davis 2013-09-30 Sold Out -0.01%$70.66 - $77.08
($73.84)
$ 96.8731%Sold Out0
NVSLee Ainslie 2013-06-30 Add0.2%$68.42 - $75.5
($72.61)
$ 96.8733%Add 39.5%741,689
NVSJohn Hussman 2013-06-30 Reduce-0.52%$68.42 - $75.5
($72.61)
$ 96.8733%Reduce -47.49%218,900
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 96.8733%Sold Out0
NVSLee Ainslie 2013-03-31 Buy 0.49%$63.3 - $71.32
($67.87)
$ 96.8743%New holding, 531689 sh.531,689
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 96.8743%Reduce -85.39%726,200
NVSIrving Kahn 2013-03-31 Reduce-0.1%$63.3 - $71.32
($67.87)
$ 96.8743%Reduce -21.03%33,456
NVSDodge & Cox 2012-12-31 Add0.11%$58.97 - $63.96
($61.79)
$ 96.8757%Add 2.65%48,438,459
NVSKen Fisher 2012-09-30 Buy 0.86%$55.24 - $61.51
($58.49)
$ 96.8766%New holding, 5086362 sh.5,086,362
NVSDodge & Cox 2012-09-30 Add0.12%$55.24 - $61.51
($58.49)
$ 96.8766%Add 3.23%47,187,759
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NVS Ruane Cunniff 2014-09-307,77200New Buy
NVS Lee Ainslie 2014-09-30272,5700.010.38New Buy
NVS Irving Kahn 2014-09-3030,36800.46+15.17%
NVS Ken Fisher 2014-09-306,015,2330.251.2+0.76%
NVS John Hussman 2014-09-30214,0000.011.7
NVS Dodge & Cox 2014-09-3050,905,4492.14.6-0.39%
NVS Mario Gabelli 2014-09-3010,19000.01-0.49%
NVS Jean-Marie Eveillard 2014-09-3012,84800-1.62%
NVS Tweedy Browne 2014-09-30283,9830.010.62-1.68%
NVS PRIMECAP Management 2014-09-3022,239,4480.922.2-6.74%
NVS HOTCHKIS & WILEY 2014-09-309,64600-98.51%
Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15545.8view

Press Releases about NVS :

    Quarterly/Annual Reports about NVS:

      News about NVS:

      Articles On GuruFocus.com
      Johnson & Johnson Riding High On Ebola Vaccines Jan 21 2015 
      Causeway International Value Fund 3Q 2014 Letter to Shareholders Dec 22 2014 
      Dividend Aristocrats In Focus Part 52 of 54: Johnson & Johnson Dec 03 2014 
      Kahn Brothers' Third Quarter Numbers Nov 07 2014 
      Tweedy Browne Global Reports its Top Five Picks of Q3 Oct 21 2014 
      Zoetis Will Benefit from Industry Trends Oct 07 2014 
      International Securities For A Diversified Income Portfolio Sep 23 2014 
      Widely Held Guru Stocks Trading In Europe Sep 22 2014 
      Why Investing Internationally Can Help Your Portfolio Sep 12 2014 
      Weekly 52-Week Highs Highlight: LLY, BG, NVS, HRL Sep 07 2014 


      More From Other Websites
      Array BioPharma shares jump on news of Novartis cancer-drug deal Jan 23 2015
      Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, the leading cause of... Jan 23 2015
      Will Novartis' (NVS) Earnings Disappoint Expectations in Q4? - Analyst Blog Jan 23 2015
      Array shares jump after drugmaker details Novartis deal Jan 23 2015
      Array shares jump after drugmaker details Novartis deal Jan 23 2015
      Novartis drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer... Jan 23 2015
      7:24 am Novartis AG announces the CHMP adopted a positive opinion for Jakavi for the treatment of... Jan 23 2015
      Up to Speed: Death of Saudi king moves needle on oil prices (Video) Jan 23 2015
      Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst Blog Jan 22 2015
      Novartis CEO says reviewing Swiss costs after franc shock Jan 22 2015
      Novartis Fourth-Quarter Profit May Drop: Earnings Preview Jan 22 2015
      We are funding part of ACA: Novartis CEO Jan 22 2015
      Teva Up on Positive Copaxone Supreme Court Ruling - Analyst Blog Jan 21 2015
      FDA Approves Novartis Psoriasis Drug Jan 21 2015
      Novartis Wins U.S. Approval for First of New Psoriasis Drugs Jan 21 2015
      Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment... Jan 21 2015
      Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for... Jan 21 2015
      Novartis' Cosentyx Approved in Europe for Plaque Psoriasis - Analyst Blog Jan 20 2015
      Supreme Court Hands Trial Courts More Power In Teva Patent Case Jan 20 2015
      New year brings change in ownership for Greensboro's Novartis Animal Health Jan 20 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK